[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,875,020
  • Shares Outstanding, K 20,041
  • Annual Sales, $ 268,090 K
  • Annual Income, $ 124,450 K
  • EBIT $ 127 M
  • EBITDA $ 157 M
  • 60-Month Beta 1.13
  • Price/Sales 22.44
  • Price/Cash Flow 38.22
  • Price/Book 6.22

Options Overview Details

View History
  • Implied Volatility 40.28% (-0.27%)
  • Historical Volatility 31.94%
  • IV Percentile 53%
  • IV Rank 25.37%
  • IV High 73.14% on 04/13/26
  • IV Low 29.11% on 12/17/25
  • Expected Move (DTE 11) 6.12 (2.07%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 14
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 1,445
  • Open Int (30-Day) 1,350
  • Expected Range 289.58 to 301.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.89
  • Number of Estimates 4
  • High Estimate $2.24
  • Low Estimate $1.22
  • Prior Year $5.68
  • Growth Rate Est. (year over year) -66.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
283.77 +4.20%
on 08/03/26
317.49 -6.86%
on 08/06/26
-20.54 (-6.50%)
since 07/10/26
3-Month
205.19 +44.11%
on 05/19/26
326.63 -9.47%
on 07/08/26
+74.29 (+33.55%)
since 05/08/26
52-Week
137.14 +115.62%
on 08/11/25
326.63 -9.47%
on 07/08/26
+145.64 (+97.05%)
since 08/08/25

Most Recent Stories

More News
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 295.70 (+0.87%)
Ligand Reports Second Quarter 2026 Financial Results

Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30...

LGND : 295.70 (+0.87%)
Ligand's Royalty Portfolio Expansion Masks Questions the Cash Flow Model Can't Answer

Barchart Research What to Expect from LGND Earnings LGND Generated August 5, 2026 Current Price $302.57 EPS Estimate $$1.34 Consensus Rating Strong Buy Average Move 4.97% Ligand's Royalty Portfolio Expansion...

LGND : 295.70 (+0.87%)
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026....

LGND : 295.70 (+0.87%)
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven  commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets,...

LGND : 295.70 (+0.87%)
XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition...

XOMA : 40.17 (-9.16%)
LGND : 295.70 (+0.87%)
XOMAP : 24.98 (+0.04%)
XOMAO : 25.00 (+0.08%)
3 Overlooked Stocks Positioned for the Next Market Rotation

Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining...

LGND : 295.70 (+0.87%)
AFL : 121.94 (-2.14%)
AUB : 41.65 (-0.31%)
Ligand Announces Closing of Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...

LGND : 295.70 (+0.87%)
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...

LGND : 295.70 (+0.87%)
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September...

GOOGL : 357.52 (+0.91%)
AAPL : 308.26 (-1.62%)
SNDK : 1,237.92 (+2.12%)
ADI : 383.92 (-1.54%)
TSLA : 330.88 (+0.70%)
STX : 800.99 (-1.45%)
AMD : 469.56 (-2.86%)
DFTX : 45.15 (-2.15%)
SPY : 773.03 (-0.03%)
META : 594.92 (+0.48%)
NOC : 577.89 (+1.10%)
FRVO : 23.92 (-7.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 311.50
2nd Resistance Point 305.44
1st Resistance Point 300.57
Last Price 295.70
1st Support Level 289.64
2nd Support Level 283.59
3rd Support Level 278.72

See More

52-Week High 326.63
Last Price 295.70
Fibonacci 61.8% 254.24
Fibonacci 50% 231.89
Fibonacci 38.2% 209.53
52-Week Low 137.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.